Inhibitor Therapeutics, Inc. (INTI)
Oxford Ledge is still expanding full research coverage of INTI. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A pharmaceutical company developing an FDA-approved antifungal drug to treat basal cell carcinoma nevus syndrome through repurposing and proprietary formulation.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-04-01
- 8-K Other material event; Financial statements and exhibits 2026-04-01
- 10-K Annual financial report with audited statements 2026-03-26
- 8-K Entry into material agreement; Financial statements and exhibits 2026-02-24
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for INTI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open INTI in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.